Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC..
In China, the emergence of a nationally widespread epidemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has appeared within a month since December 7, 2022. To evaluate the risk factors for suffering from coronavirus disease 2019 (COVID-19) pneumonia due to infection with SARS-CoV-2 in different kinds of interstitial lung disease (ILD) patients with diverse immunizations, we conducted this retrospective study on 525 patients with ILDs who underwent regular follow-up in our ILD clinic. Among them, 128 ILD patients (24.4%) suffered from COVID-19 pneumonia after SARS-CoV-2 infection. Patients were older with a male predominance in the pneumonia group than in the nonpneumonia group (65.0 ± 10.0 years vs. 56.4 ± 11.7 years, p < 0.001, 55.5% vs. 39.5%, p = 0.002, respectively). Connective tissue disease-associated ILD (CTD-ILD) (25%), idiopathic pulmonary fibrosis (23.4%), and interstitial pneumonia with autoimmune features (21.1%) were the main pre-existing ILDs in the pneumonia group. In Cox multivariable analysis, only male sex and corticosteroid use were risk factors for COVID-19 pneumonia after infection. Two or three doses of vaccination were a protective factor for pre-existing ILD patients suffering from COVID-19 pneumonia. More than two doses of vaccination were strongly recommended for pre-existing ILD patients, particularly for males who were administered corticosteroids.
| Errataetall: |
CommentIn: J Med Virol. 2023 Nov;95(11):e29207. - PMID 37916851 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Journal of medical virology - 95(2023), 9 vom: 08. Sept., Seite e29098 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shao, Chi [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.09.2023 Date Revised 10.01.2024 published: Print CommentIn: J Med Virol. 2023 Nov;95(11):e29207. - PMID 37916851 Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.29098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362046557 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362046557 | ||
| 003 | DE-627 | ||
| 005 | 20240114233350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.29098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM362046557 | ||
| 035 | |a (NLM)37707416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shao, Chi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk factors associated with COVID-19 pneumonia in Chinese patients with pre-existing interstitial lung disease during the SARS-CoV-2 pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2023 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Med Virol. 2023 Nov;95(11):e29207. - PMID 37916851 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. | ||
| 520 | |a In China, the emergence of a nationally widespread epidemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has appeared within a month since December 7, 2022. To evaluate the risk factors for suffering from coronavirus disease 2019 (COVID-19) pneumonia due to infection with SARS-CoV-2 in different kinds of interstitial lung disease (ILD) patients with diverse immunizations, we conducted this retrospective study on 525 patients with ILDs who underwent regular follow-up in our ILD clinic. Among them, 128 ILD patients (24.4%) suffered from COVID-19 pneumonia after SARS-CoV-2 infection. Patients were older with a male predominance in the pneumonia group than in the nonpneumonia group (65.0 ± 10.0 years vs. 56.4 ± 11.7 years, p < 0.001, 55.5% vs. 39.5%, p = 0.002, respectively). Connective tissue disease-associated ILD (CTD-ILD) (25%), idiopathic pulmonary fibrosis (23.4%), and interstitial pneumonia with autoimmune features (21.1%) were the main pre-existing ILDs in the pneumonia group. In Cox multivariable analysis, only male sex and corticosteroid use were risk factors for COVID-19 pneumonia after infection. Two or three doses of vaccination were a protective factor for pre-existing ILD patients suffering from COVID-19 pneumonia. More than two doses of vaccination were strongly recommended for pre-existing ILD patients, particularly for males who were administered corticosteroids | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) pneumonia | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a risk factor | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Shi, Yujie |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ruxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiangning |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Keqi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Mengzhao |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zuojun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 95(2023), 9 vom: 08. Sept., Seite e29098 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:9 |g day:08 |g month:09 |g pages:e29098 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 9 |b 08 |c 09 |h e29098 | ||